AIM ImmunoTech (AIM) Cash & Current Investments (2010 - 2026)

AIM ImmunoTech (AIM) has 17 years of Cash & Current Investments data on file, last reported at $5.9 million in Q1 2026.

• Quarterly Cash & Current Investments rose 161.64% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 161.64% YoY) and the FY2025 annual result came in at $3.0 million, down 69.36% from the prior year.
• Cash & Current Investments advanced to $5.9 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $41.8 million in Q2 2022 to a low of $835000.0 in Q2 2025.
• A 5-year average of $17.0 million and a median of $10.9 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments plunged 91.7% — and 2026, when it jumped 161.64%.
• Tracing AIM's Cash & Current Investments over 5 years: stood at $34.2 million in 2022, then tumbled by 61.77% to $13.1 million in 2023, then slipped by 23.91% to $9.9 million in 2024, then sank by 69.36% to $3.0 million in 2025, then jumped by 92.94% to $5.9 million in 2026.
• The last three Cash & Current Investments figures came in at $5.9 million (Q1 2026), $3.0 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.